Exact Sciences Revenues More Than Double on Cologuard Sales | GenomeWeb

NEW YORK (GenomeWeb) – Exact Sciences reported before the opening of the market on Tuesday that its second quarter revenues more than doubled year over year thanks in large part to a 160 percent increase in the number of Cologuard colorectal cancer screening tests completed during the quarter.

For the three months ended June 30, the molecular diagnostics firm reported revenues of $21.2 million, up from $8.1 million a year ago, and beating the consensus Wall Street estimate of $18.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.